FILTER

LATEST INTERVIEWS

Eduardo Cossio Chirinos

CEO, INCIMMET
INCIMMET speaks with GBR of its long experience as a contractor for mining projects in Peru and Colombia.

Robert Bloder

CHIEF BUSINESS OFFICER, ASCENDIA PHARMACEUTICALS
Ascendia Pharmaceuticals recounts the requirements to succeed in the CDMO space.

Jigar Raythatha

PRESIDENT & CEO, CONSTELLATION PHARMACEUTICALS
Constellation Pharmaceuticals explains its therapy for myelofibrosis and introduces its discovery engine.

Mike da Costa

CEO, GLOBAL MINING, MURRAY & ROBERTS (M&R)
Murray and Roberts in South Africa explains how technology is transforming mine development and shaft sinking.

Joe Walsh

MANAGING DIRECTOR, LEPIDICO
Lepidico is fast developing its integrated lithium operation, from its’ mine in Namibia to producing derived chemicals from plants to be built in UAE.

Bruce Anderson

BRUCE ANDERSON, CEO, 247SOLAR
247Solar explains to GBR why its unique Heat2Power turbines can provide clean, reliable and cheap energy to off-grid mines.

Marcelo Schumacker

COUNTRY DIVISION MANAGER, ABB CHILE
ABB explains why Chile provides an excellent market for its mining technologies.

Sandro Tavonatti

CEO, SIGDO KOPPERS INGENIERÍA Y CONSTRUCCIÓN (SKIC)
Sigdo Koppers Ingeniería y Construcción (SKIC) explains how it operates with Chile’s largest mines.

Florencio Castro & Alexandra Almenara

VP – PERU & VP ENVIRONMENT AND SUSTAINABILITY – SOUTH AMERICA, AUSENCO
Ausenco in Peru relates how it is developing the capacity to provide an integral service of engineering, environmental and social services to any project at any stage of their life cycle.

Andrea Lodetti

CEO, BORMIOLI PHARMA
Bormioli Pharma discusses its plans to maintain its expansion.

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENT PUBLICATIONS

United States Life Sciences 2025 - Digital Interactive

Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.

PARTNER EVENTS